*Note: Validation studies have already been performed on the Oncotype DX Breast Cancer Assay for patients with pre-invasive or DCIS, node-negative and node-positive, estrogen-receptor-positive (ER+) breast cancer; for single gene reporting quantitative of ER (estrogen receptor), PR (progesterone receptor negative) and HER2 (human epidermal growth factor receptor 2) genes, and for patients treated with Tamoxifen or an Aromatase Inhibitor.
The breast cancer test is currently commercially available. For detailed information about the Oncotype DX breast cancer test, please call: (866) ONCOTYPE or visit www.oncotypedx.com
|New Targets in Development:
Chemotherapy benefit with specific drugs/drug classes (e.g., taxanes, anthacyclines, angiogenesis inhibitors, PARP inhibitors): Development stage
|U.S. Incidence of Breast Cancer (includes DCIS/pre-invasive breast cancer)
|Global Incidence of Breast Cancer
About Invasive Breast Cancer
Breast cancer is a cancer that forms in the breast tissue, most often in the lobules (glands where milk is made) or ducts (tubes that carry milk to the nipple). Although most cases of breast cancer occur in women, it can also occur in men. Among women (in both the U.S. and worldwide), breast cancer is by far the most common type of cancer.
About Ductal Carcinoma In Situ of the Breast (DCIS)/Pre-Invasive Breast Cancer
DCIS is an early or pre-invasive form of breast cancer that is being diagnosed at an increasing rate, with an estimated 45,000 U.S. cases reported in 20092. Unlike invasive breast cancer, the tumor cells in DCIS are not found outside of the ducts within the breast.
Chemotherapy Benefit with Specific Drugs/Drug Classes (e.g., taxanes, anthracyclines, angiogenesis inhibitors, PARP inhibitors)
Although it has been shown that selection of multi-drug therapy provides benefit for certain patients with early-stage breast cancer, it is not yet possible to identify which patients benefit the most from which drug combinations. As the number of treatment options increases, it has become even more important to understand which patients would benefit from which drugs. Studies are in progress to develop clinical tests to guide selection of specific drugs and/or drug classes, such as taxanes, anthracyclines, angiogenesis inhibitors, and PARP inhibitors.
Additional Breast Cancer Patient Resources:
- My Breast Cancer Treatment Coach website – a free, interactive online tool designed to help patients with breast cancer better understand their disease and potential treatments.
- My Breast Cancer Treatment website – a patient education website with survivor testimonials and additional information about personalized breast cancer treatment.
Information about the Oncotype DX breast cancer test for German, Spanish & Japanese Patients.
Contact Genomic Health for more information about the Oncotype DX breast cancer test.
For more information about breast cancer, visit the National Cancer Institute's Breast Cancer page or the non-profit www.breastcancer.org.
Learn more about additional Genomic Health products in development:
- Mattson Jack, CancerMPact November 2010 (2011 incidence).
- Company figure adapted from MattsonJack, CancerMpact, November 2010 (2011 incidence)
- Globocan 2008.